Skip to content

A randomized controlled trial of moxibustion, far-infrared magnetic therapy patch and cold compress gel in the treatment of myofascial pain syndrome

A randomized controlled trial of moxibustion, far-infrared magnetic therapy patch and cold compress gel in the treatment of myofascial pain syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006152
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myofascial pain syndrome

Interventions

Diclofenac diethylamine emulsion treatment group:Diclofenac diethylamine emulsion treatment
Cold compress gel treatment group:Cold compress gel treatment
Moxibustion,far infrared magnetic therapy stick combined with cold compress gel treatment group:Moxibustion, far infrared magnetic therapy stick combined with cold compress gel treatment

Sponsors

Sanbo Brain Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the clinical diagnostic criteria of TCM and Western medicine for myofascial pain syndrome; (2) Must be between 18 and 80 years old; (3) They have a detailed understanding of the subject, are willing to accept the treatment plan prescribed by the subject, and voluntarily sign the informed consent; (4) Volunteer to cooperate with the researcher to complete the research.

Exclusion criteria

Exclusion criteria: (1) Patients suffering from blood diseases, serious liver diseases, tumors and other poor coagulation function or critically ill condition; (2) patients suffering from acute infectious diseases; (3) Patients with trauma, wound infection or local wounds; (4) Those who have used relevant test materials in the past and have allergies; (5) Patients with recent open surgery; (6) Patients with rheumatic diseases or immune diseases who need to take hormones for a long time; (7) Patients with systemic infection.

Design outcomes

Primary

MeasureTime frame
NRS score;

Countries

China

Contacts

Public ContactBaoguo Wang

Sanbo Brain Hospital of Capital Medical University

wbgttyy@163.com13370185075

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026